|
Darbepoetin alfa
resources
|
|
|
|
|
|
DRUG INFO
Darbepoetin alfa
Drug Name:
Darbepoetin alfa
Indication: For treatment of anemia (from renal transplants or certain HIV treatment)
Pharmacology: Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
Mechanism Of Action: Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
Drug Category: Antianemic Agents; hematopoietic agents (20:16.00)
Brand Names/Synonyms: Erythropoietin precursor;Epoetin; Aranesp (Amgen Inc.)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human erythropoietin
Chemical Formula: C815H1317N233O241S5
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00032
CAS Registry Number: 11096-26-7
|
|
|
|
|
|
Darbepoetin alfa News
(When available)
[an error occurred while processing this directive]
Computer Modeling Suggests Cost-Effectiveness of Once Weekly ... Jan 13, 2006
Cancer Consultants (press release), Researchers from France have performed a Markov analysis, which concluded that weekly Aranesp (darbepoetin) was cost-effective for prevention of anemia in ...
Myelodysplastic syndrome: improvements in hemoglobin levels and ... Jan 8, 2006
Xagena.it, Interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp ( Darbepoetin alfa ) administered every three weeks to treat anemia in patients with ...
Aranesp® Improves Chemotherapy-Induced Anemia Without Adversely ... Jan 6, 2006
Cancer Consultants (press release), A combined analysis of four clinical trials of Aranesp® (darbepoetin alfa) for the treatment of chemotherapy-induced anemia suggests that Aranesp reduces the ...
Darbepoetin Alfa (Aranesp) Data Suggests Major Response in Anemic ... Dec 16, 2005
DG News ATLANTA, GA -- December 16, 2005 -- Interim results from a phase 2, open-label study indicate that darbepotin alfa (Aranesp) 500 mcg taken Q3W appears to be ...
Benefits Of Aranesp Dosed Every Three Weeks For Chemotherapy ... Dec 12, 2005
Medical News Today (press release), ...company, today announced interim results from the first multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial of Aranesp® (darbepoetin alfa ...
Investigative Drug Aranesp (Darbepoetin) Effective for ... Dec 14, 2005
DG News ATLANTA, GA -- December 14, 2005 -- Treatment of chemotherapy-induced anemia with the investigative agent darbepoetin (Aranesp(R)) administered every 3 weeks ...
Oncologist warns of cancer-related anaemia Jan 13, 2006
Irish Medical News, ...“Aranesp (darbepoetin alfa) not only helps correct anaemia ... Dr Glaspy made his comments at a recent meeting in Dublin, supported by Amgen, makers of Aranesp.
Amgen starting nephrology institute to aid kidney patients Jan 6, 2006
Ventura County Star (subscription), Of Amgen's eight drugs on the market, three deal with kidney failure. Aranesp treats anemia associated with chronic renal failure. ...
Medicare expands tier pricing system Jan 3, 2006
USA Today ...of the drug rather than a flat dollar amount — are such expensive treatments as Remicade and Enbrel for rheumatoid arthritis, Procrit and Aranesp for anemia ...
Amgen CEO expects more Epogen patent battles Jan 9, 2006
Reuters ...on kidney dialysis. Amgen, based in Thousand Oaks, California, also sells Aranesp, a longer-lasting version of Epogen. It is marketed ...
Last quarter was hit-or-miss for drugmakers Jan 11, 2006
Newark Star Ledger, Results are expected to be driven by sales of Aranesp, a treatment for anemia in people with chronic renal failure and cancer patients on chemotherapy, as well ...
Drug cuts transfusions in half for chemo patients Dec 15, 2005
Cancerfacts.com, It is the first large, multi-center, comparison trial of Aranesp® (darbepoetin alfa) administered every three weeks in cancer patients with anemia resulting ...
Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs Dec 23, 2005
The Ledger, ...ranging from the Swiss giant Roche to Silicon Valley start-ups - are developing anemia drugs to compete against Epogen and Aranesp, the blockbusters that will ...
Amgen patent attacked Dec 24, 2005
Los Angeles Daily News, ...companies - ranging from the Swiss giant Roche to Silicon Valley startups - are developing anemia drugs to compete against Epogen and Aranesp, the blockbusters ...
Approval Process Still Not Set Dec 22, 2005
New York Times, Amgen's patents on Epogen and Aranesp are not the only barriers to competing drugs in this country. The federal government still ...
Revlimid® Approved for Myelodysplastic Syndromes Dec 28, 2005
Cancer Consultants (press release), ...disease and may be managed with blood transfusions (referred to as transfusion-dependent) or agents that stimulate red blood cell growth, such as Aranesp®. ...
Drug increases hemoglobin in Myelodysplastic Syndrome Dec 13, 2005
MedIndia, Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve ...
Amgen "neutral weight" Dec 14, 2005
New Ratings ...yesterday, the analyst mentions that the company recently presented key data for its supportive care agents for anemia and thrombocytopenia, Aranesp and AMG 531 ...
Amgen drug could offer option for platelet disease Dec 13, 2005
Ventura County Star (subscription), Amgen also reported study results from Aranesp, its anti-anemia drug. The results showed Aranesp helped increase hemoglobin in patients ...
Biotechnology drug costs scrutinized Jan 3, 2006
Ventura County Star (subscription), About 40 percent of the plans have created this fourth tier for drugs such as Amgen Inc.'s Aranesp for anemia, which costs about $36,000 a year, Serono SA and ...
Amgen initiated with "buy" Dec 16, 2005
New Ratings ...note published this morning, the analyst mentions that the performance of Amgen's core business remains robust, driven by the company's Aranesp, Neulasta and ...
|
|
|
